Patient Preference for Treatment Mode of Biologics in Rheumatoid Arthritis: A 2020 Web-based Survey in Japan

Kishimoto, Mitsumasa; Yamairi, Fumiko; Sato, Noriko; Kobayashi, Jun; Yamauchi, Saori; Iwasaki, Tetsuya

doi:10.1007/s40744-021-00325-9

Cited by 12 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study employed the DCE method to estimate RA patients' preferences for different attributes of self-injection devices. Individual data from 114 patients were analyzed to explore how different features (operation steps, injection pain, feedback indication, needle visibility, needle protection, size, out-of-pocket costs) influence their choice of injection The findings of this study are consistent with several previous studies 19,[26][27][28][29][30] in patients with rheumatic diseases about their preferred attributes in self-injection devices. For instance, Boeri et al found that injection speed control and injection reminders were preferred features for RA patients when selecting self-injection devices.…”

Section: Discussionsupporting

confidence: 82%

“…The attributes describing self-injection devices were developed based on the differences in existing injection devices and the review of published literature. 19,[26][27][28][29][30] Potential attributes included ease of use, safety, indicators, needle visibility, practicality, out-of-pocket costs. The out-of-pocket cost indicated the cost of the injection device per injection.…”

Section: Dce Questionnaire Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in China

Yan¹,

Zhao²,

Ming³

et al. 2022

PPA

View full text Add to dashboard Cite

Objective Rheumatoid arthritis (RA) is increasingly treated with biologics, which is commonly administered by injection devices. The aim of this study is to evaluate patients’ preferences for self-injection devices in RA, and to elicit their willingness to pay (WTP) for injector devices in China. Methods RA patients were recruited from Beijing, Shanghai, Guangzhou, Chengdu, Wuhan and Xi’an in China. A discrete choice experiment (DCE) was employed to elicit patient preferences. Patients were presented with 15 choice sets that consisted of seven attributes, which were developed based on literature review and further validated by physicians. The seven attributes were as follows: operation steps, injection pain, feedback indication, needle visibility, needle protection, size and out-of-pocket costs. A mixed logit model was used to analyze the relative importance of seven attributes and to calculate the WTP for a changed attribute level. Results Analyses included 114 adults with RA (mean age of 44.6 years old). When choosing the injection device, all attributes had significant influence. Among nonmonetary attributes, very slight injection pain was the most preferred for patients, followed by auto-injection method, thicker size, hidden needle, with needle protection and multiple feedback indication. Patients had a negative preference for increasing out-of-pocket costs. Patients were willing to pay CNY 45.26 for improving slight injection pain to very slight injection pain, CNY 13.26 for the auto-injection method, CNY 12.22 for the thicker size, CNY 10.06 for the hidden needle, CNY 9.82 for needle protection, and CNY 9.70 for multiple feedback indicators. Conclusion The results suggested that injection pain was the most important attribute for RA patients. Meanwhile, all other enhanced attributes of self-injection devices also significantly influence patients’ selection on injection devices. Findings suggested that there is significant potential value in developing self-injection devices that could further help improve treatment adherence and promote patient-centered care in autoimmune diseases.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Dce Questionnaire Developmentmentioning

confidence: 99%

Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in China

Yan¹,

Zhao²,

Ming³

et al. 2022

PPA

View full text Add to dashboard Cite

show abstract

“… 32 , 37 , 50 – 54 While there may be perks in self-administration of biologics in severe asthma, they may be associated with challenges including needle phobia, fear and anxiety, injection-site reactions and pain, non-adherence, erroneous administration, and lack of patient faith. 55 , 56 …”

Section: Expert Opinionmentioning

confidence: 99%

Dupilumab and tezepelumab in severe refractory asthma: new opportunities

Ragnoli

Morjaria

Pignatti

et al. 2022

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Bronchial asthma is a chronic inflammatory condition with increasing prevalence worldwide that may present as heterogeneous phenotypes defined by the T2-mediated pattern of airway inflammation T2-high and T2-low asthma. Severe refractory asthma includes a subset of asthmatic patients who fail to control their disease despite maximal therapy and represent a group of patients needing marked resource utilization and hence may be eligible to add-on biological therapies. Among the new biologics, we focused our attention on two monoclonal antibodies: dupilumab, exerting a dual blockade of cytokine (interleukin (IL)-4 and IL-13) signaling; and tezepelumab, acting at a higher level preventing the binding of thymic stromal lymphopoietin (TSLP) to its receptor, thus blocking TSLP, IL-25, and IL-33 signaling, hence modulating airway T2 immune responses. With their different mechanisms of action, these two biologics represent important options to provide an enhanced personalized treatment regimen. Several clinical trials have been conducted testing the efficacy and safety of dupilumab in severe refractory asthmatic patients showing improvements in lung function, asthma control, and reducing exacerbations. Similar results were reported with tezepelumab that, differently from dupilumab, acts irrespectively on eosinophilic or non-eosinophilic phenotype. In this review, we provide an overview of the most important highlights regarding dupilumab and tezepelumab characteristics and mechanism of action with a critical review of the principal results of clinical (Phase II and III) studies concluded and those still in progress.

show abstract

“…All questions were designed by the researcher with reference to the ideas in the relevant articles. [18][19][20] Consistency Analysis in Pre-survey In the present survey, 10 participants were randomly selected to fill out the questionnaire again by random sampling method 10 days after the first time, and by analyzing and comparing the results of the two questionnaires. The kappa statistic was used for the consistency test, 21 when the kappa coefficient was <0, the consistency strength was poor, 0.00-0.20, slight, 0.21-0.40, fair, 0.41-0.60, moderate, 0.61-0.80, substantial, and 0.81-1.00, almost perfect.…”

Section: Questionnaire Designmentioning

confidence: 99%

Preference of Orthopedic Practitioners Toward the Use of Topical Medicine for Musculoskeletal Pain Management in China: A National Survey

Mei

Zhang

et al. 2022

Orthopaedic Surgery

View full text Add to dashboard Cite

Objective: Musculoskeletal pain is having growing impacts worldwide with clinical challenge in pain management. The purpose of the present study is to investigate the preferences of orthopedic surgeons of China for using medicine in musculoskeletal pain.Methods: A questionnaire was developed, including the following domains, personal information, medication preference for pain treatment, and perceptions of topical medicine. Ten participants were selected to confirm the consistency of questionnaire. A cross-sectional survey was conducted in orthopedic physicians with different specialties in different regions of China via the online survey platform. The participants' survey results were analyzed one-way and multi-way using chi-square test and logistic regression.

show abstract

Patient Preference for Treatment Mode of Biologics in Rheumatoid Arthritis: A 2020 Web-based Survey in Japan

Cited by 12 publications

References 17 publications

Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in China

Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in China

Dupilumab and tezepelumab in severe refractory asthma: new opportunities

Preference of Orthopedic Practitioners Toward the Use of Topical Medicine for Musculoskeletal Pain Management in China: A National Survey

Contact Info

Product

Resources

About